Healthy gut bacteria may improve the success of cancer treatment – study

Researchers say the findings are a key step forward in the fight against multiple types of cancer.

Healthy gut bacteria may improve the success of cancer treatment – study (Lynne Cameron/PA)
Healthy gut bacteria may improve the success of cancer treatment – study (Lynne Cameron/PA)

Healthy gut bacteria improves the success of cancer treatment, a new study suggests.

Researchers say the findings are a key step forward in the fight against multiple types of cancer including melanoma, the most deadly form of skin cancer.

As less than 50% of people respond positively to immunotherapy for melanoma, finding ways to improve this number is crucial, the scientists suggest.

The study found that melanoma patients who receive therapy to help their immune system kill cancer cells respond differently to treatment depending on the types of microbes in their gut.

The new research suggests the microorganisms that hinder therapy have more of an influence than ones that are beneficial.

This new study could have a major impact on oncology and medicine in general

Dr Karla Lee

Dr Karla Lee, clinical researcher at King’s College London and first author of the study, said: “Preliminary studies on a limited number of patients have suggested that the gut microbiome, as an immune system regulator, plays a role in the response of each patient to cancer immunotherapy, and particularly in the case of melanoma.

“This new study could have a major impact on oncology and medicine in general.”

The microbiome, the set of microorganisms that live in the intestines, can be altered through dietary changes, probiotics and faecal transplantation.

Researchers suggest understanding the characteristics of the microbiome could allow doctors to change a patient’s microbiome before starting treatment.

Co-author Professor Tim Spector from King’s College London said: “This study shows the chances of survival based on healthy microbes nearly doubled between subgroups.

“The ultimate goal is to identify which specific features of the microbiome are directly influencing the clinical benefits of immunotherapy to exploit these features in new personalised approaches to support cancer immunotherapy.

“But in the meantime, this study highlights the potential impact of good diet and gut health on chances of survival in patients undergoing immunotherapy.”

The study put together the largest group of patients with melanoma and samples of their gut microbiome from five clinical centres in the UK, the Netherlands and Spain.

Researchers carried out a large-scale sequencing of the gut microbiome to investigate whether there was a link between the make up of the gut microbiome and response to immunotherapy.

They found a complex association that involves different bacterial species in different patient groups.

The presence of three types of bacteria appeared to be associated with a better immune response.

The research also found that the microbiome itself is strongly influenced by factors including the make-up of the patient’s body and diet.

Co-author Professor Nicola Segata from the University of Trento, Italy, said: “Our study shows that studying the microbiome is important to improve and personalise immunotherapy treatments for melanoma.

“However, it also suggests that because of the person-to-person variability of the gut microbiome, even larger studies must be carried out to understand the specific gut microbial features that are more likely to lead to a positive response to immunotherapy.”

The study is published in Nature Medicine and co-ordinated by King’s College London, CIBIO Department of the University of Trento and European Institute of Oncology in Italy, University of Groningen in the Netherlands and funded by the Seerave Foundation.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in